Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared to healthy skin, we observed increased expression of psoriasin and RNAse7 (both mostly in stratum granulosum of the epidermis), HBD-2 (in the cellular infiltrate of the dermis), and LL37 (mostly in and around blood vessels and glands) in PLE lesional skin, a similar expression profile as present in psoriatic skin and different to that of AD (with little or no expression of psoriasin, RNAse7, HBD-2, and LL37).
|
29044786 |
2018 |
Dermatitis, Atopic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of antimicrobial peptides such as LL-37 and β-defensin-2 was also increased by exposure to glyoxal in the skin of both naïve and AD rats.
|
29496360 |
2018 |
Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LL37 mRNA expression was decreased in lesions of AD-like GVHD and LP-like GVHD patients (P = 0.005 and P = 0.008, vs. HCs, respectively). hBD2 mRNA expression was increased in skin lesions of AD-like GVHD and LP-like GVHD patients (P = 0.002 and P< 0.001, vs. HCs, respectively).
|
28584210 |
2017 |
Dermatitis, Atopic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The modulation by LL-37 of the keratinocyte proinflammatory responses induced by cytokine milieus and dsRNA suggests novel roles for LL-37 in skin inflammation such as the promotion of IL17/IL-22/IL-6-associated psoriasis and suppression of TSLP-associated atopic dermatitis.
|
23524263 |
2013 |
Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BV and TA treatment in AD led to a significant reduction in AMP expression; protein expression of human beta-defensins (hBD)-2 and hBD-3, psoriasin, RNase 7 and cathelicidin LL-37 was below the level in skin of healthy controls.
|
21707760 |
2011 |
Dermatitis, Atopic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, the mechanism to upregulate hCAP18 following vitamin D treatment was functional in lesional as well as in non-lesional AD indicating that the CAMP gene is normally regulated in this respect.
|
19645825 |
2010 |
Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the expression of LL-37 in lesional skin compared with nonlesional skin in patients with different severity of AE, patients with other eczema and healthy subjects.
|
19309368 |
2009 |
Dermatitis, Atopic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore increasing production of skin LL-37 might prevent herpes infection in patients with AD.
|
16630942 |
2006 |
Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The epidermal expression of antimicrobial peptides (AMPs) such as human beta-defensin (hBD)-2 and cathelicidin LL-37 is downregulated in atopic eczema (AE) as compared with psoriasis.
|
17107401 |
2006 |
Dermatitis, Atopic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of LL-37 was analyzed in monocyte-derived dendritic cells (MDDCs) generated from healthy individuals and patients with AE by Western blotting and the corresponding cDNA by real-time quantitative RT-PCR.
|
16512803 |
2006 |
Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
And expression of LL-37 in skin biopsy specimens from patients with atopic dermatitis and psoriasis was determined by immunohistochemical analysis.
|
16100459 |
2005 |
Dermatitis, Atopic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We compared the levels of expression of LL-37 and human beta-defensin 2 (HBD-2) in inflamed skin from patients with atopic dermatitis and from those with psoriasis.
|
12374875 |
2002 |